Long lasting responses to adoptive T-cell therapy in relapsed EBV-related nasopharyngeal carcinoma
Simona Secondino(Azienda Ospedaliera Treviglio), Paolo Pedrazzoli(Policlinico San Matteo Fondazione), Cristiana Bergamini(Fondazione IRCCS Istituto Nazionale dei Tumori), I. Pisani(Unknown), Antonella Gurrado(Policlinico San Matteo Fondazione), Lisa Licitra(University of Milan), Anna Pagani(Istituti di Ricovero e Cura a Carattere Scientifico), Marco Zecca(Policlinico San Matteo Fondazione), Jessica Bagnarino(Policlinico San Matteo Fondazione), Patrizia Comoli(Policlinico San Matteo Fondazione), Cesare Perotti(Istituti di Ricovero e Cura a Carattere Scientifico), Ilaria Imarisio(University of Pavia), Michela Casanova(Fondazione IRCCS Istituto Nazionale dei Tumori), Sabrina Basso(Istituti di Ricovero e Cura a Carattere Scientifico), Paolo Bossi(Humanitas University)
Cited by 0
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
|Cancer|2020|1.3k
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study
|European Journal of Cancer|2015|486